 | Up a level |
Edelmann, J., Haferlach, C., Saub, J., Teleanu, V, Florence, C., Leblonde, V, Delmer, A., Buehler, A., Gribben, J. G., Hallek, M., Doehner, H. and Stilgenbauer, S. (2014). Genomic characterization of primary ultra high-risk and refractory chronic lymphocytic leukemia: Results from the CLL2O trial. Oncol. Res. Treat., 37. S. 220 - 221. BASEL: KARGER. ISSN 2296-5262
Schlenk, R. F., Paschka, P., Krauter, J., Luebbert, M., Brossart, P., Salih, H. R., Theobald, M., Fiedler, W., Wulf, G., Kirchner, H., Hertenstein, B., Heide, F., Westermann, J., Griesshammer, M., Wattad, M., Goetze, K., Girschikofsky, M., Kuendgen, A., Koller, E., Rudolph, C., Heuser, M., Thol, F., Goehring, G., Teleanu, V, Weber, D., Gaidzik, V., I, Doehner, K., Ganser, A. and Doehner, H. (2015). Clinical outcome in older AML patients not fit for intensive chemotherapy: Results of the population-based AMLSG-BiO (NCT01252485) registry study of the German-Austrian AML study group. Oncol. Res. Treat., 38. S. 121 - 123. BASEL: KARGER. ISSN 2296-5262